Abstract: The present application discloses a class of guaianolide sesquiterpene lactone derivatives and pharmaceutical use thereof. The guaianolide sesquiterpene lactone derivative or a pharmaceutically acceptable salt thereof is shown as general formula I. In the present application, a class of novel guaianolide sesquiterpene lactone derivatives are found by structural optimization with abundant natural ingredients such as parthenolide and dehydrocostus lactone as raw materials, which derivatives have good inhibitory activity on the activation of the NLRP3 inflammasome, and the chemical stability, water solubility and oral bioavailability of which are significantly improved, and it is verified by experiments that the derivatives have inhibitory effects on the activity of the NLRP3 inflammasome and have potential pharmaceutical applications.

Abstract: The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR? mutation.

Abstract: The present invention relates an elevating apparatus based on a hetero-oriented non-isometric, dual-spiral drive structure, comprising a first carrier and a second carrier, further comprising a first support and a second support that are telescoped together in a manner that they can rotate with respect to each other, the first support is provided with a first recessed portion and a first raised portion that shares the same spiral direction and spiral pitch, the second support is provided with a homo-oriented, isometric, dual-spiral second recessed portion that has a spiral direction different from that of the first recessed portion. The carrier of the present invention is provided in a simply-supported-beam, and the carrier force can be achieved without additional weight, and the operation is stable and reliable.

Abstract: A novel dry powder inhaler. By providing a plurality of capsule chambers (1a, 1b, 1c, 1d) arranged in parallel in a capsule dry powder inhalation device, a medicine dispenser containing active components of a composite product or their mixture separately is provided. The dry powder inhaler has a simple structure and is convenient to operate. In addition, the parameters of air inlet channels and an air outlet channel can be adjusted by means of each capsule chamber (1a, 1b, 1c, 1d) according to the properties of powder of a medicine or a combination, so as to provide an appropriate particle distribution for each active component.

Abstract: A rate negotiation method is provided. A first device switches a fiber transmission rate of a first port of the first device to a first fiber transmission rate based on a preset switching direction within a rotation period of a first fiber transmission rate set. The first device sends a negotiation packet to a second device through the first port of the first device within a duration of the first fiber transmission rate. If a response packet is received from the second device through the first port of the first device within the duration of the first fiber transmission rate, the first port of the first device is controlled to communicate with the second device based on the first fiber transmission rate.

Abstract: The present application relates to the field of pharmaceutical technology, specifically to the crystal habit and crystalline powder preparation of quinoline derivatives, and more specifically, to the crystal habit and crystalline powder preparation of anlotinib dihydrochloride. The compound of formula II disclosed herein is a crystalline powder with a flaky crystal habit having a specific surface area ?10 m2/g and a particle-size distribution of X50?50 ?m and/or X90?500 ?m, such that a large specific surface area is provided without reducing the particle size of the drug by a physical method under the condition of a broad particle-size distribution, and the drug can rapidly dissolving. In addition to excellent dissolution property, the crystalline powder is also beneficial to industrial manufacturing, featuring simplified process and cost-efficiency.

Abstract: Disclosed are a pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance. The pharmaceutical composition includes a therapeutically effective amount of a short peptide and morphine as active ingredients, and a pharmaceutically-acceptable carrier. The short peptide is a peptide consisting of an amino acid sequence shown in SEQ ID NO: 1 or a pharmaceutically-acceptable salt thereof. In the method, the short peptide and morphine are administered to a subject simultaneously; or the short peptide is injected to the subject followed by administration of the morphine; or a pharmaceutical composition including the short peptide and morphine is administered to the subject.

Abstract: A pharmaceutical composition of a tricyclic PDE3/PDE4 dual inhibitor compound and a preparation method therefor, specifically relating to a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, and use thereof

Abstract: The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.

Abstract: A solid pharmaceutical composition comprising a quinazoline derivative or a medicinal salt thereof, and a preparation method therefor. Specifically, provided is a solid pharmaceutical composition comprising N6-(1-acryloylpiperidin-4-yl)-N4-(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine or a medicinal salt thereof, and a preparation method therefor and use thereof.

Abstract: The present invention relates an elevating apparatus based on a hetero-oriented non-isometric, dual-spiral drive structure, comprising a first carrier and a second carrier, further comprising a first support and a second support that are telescoped together in a manner that they can rotate with respect to each other, the first support is provided with a first recessed portion and a first raised portion that shares the same spiral direction and spiral pitch, the second support is provided with a homo-oriented, isometric, dual-spiral second recessed portion that has a spiral direction different from that of the first recessed portion. The carrier of the present invention is provided in a simply-supported-beam, and the carrier force can be achieved without additional weight, and the operation is stable and reliable.

Abstract: Disclosed are a pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance. The pharmaceutical composition includes a therapeutically effective amount of a short peptide and morphine as active ingredients, and a pharmaceutically-acceptable carrier. The short peptide is a peptide consisting of an amino acid sequence shown in SEQ ID NO: 1 or a pharmaceutically-acceptable salt thereof. In the method, the short peptide and morphine are administered to a subject simultaneously; or the short peptide is injected to the subject followed by administration of the morphine; or a pharmaceutical composition including the short peptide and morphine is administered to the subject.

Abstract: The disclosure provides an experimental calibration method of a redundant inertial measurement unit including, step (1), establishing an installation angle model using a cone descriptive scheme, and obtaining a relationship of an angular speed of a carrier and an angular speed measured by each gyroscope, step (2), establishing a standard calibration model of the redundant inertial measurement unit based on a relationship between a sensor coordinate system and a carrier coordinate system, step (3), establishing a state equation and a measurement equation of a filter, step (4), performing a row amplification of measurement amounts based on the measurement equation established in step (3), and obtaining an amplificated measurement equation for improving observability, and step (5), obtaining a Jacobi matrix and a Hessian matrix based on the amplificated measurement equation, and estimating error parameters by an extended Kalman filtering algorithm based on a second-order Taylor expansion.

Abstract: A rate negotiation method is provided. A first device switches a fiber transmission rate of a first port of the first device to a first fiber transmission rate based on a preset switching direction within a rotation period of a first fiber transmission rate set. The first device sends a negotiation packet to a second device through the first port of the first device within duration of the first fiber transmission rate. If a response packet is received from the second device through the first port of the first device within the duration of the first fiber transmission rate, the first port of the first device is controlled to communicate with the second device based on the first fiber transmission rate.

Abstract: The present application relates to the field of pharmaceutical technology, specifically to the crystal habit and crystalline powder preparation of quinoline derivatives, and more specifically, to the crystal habit and crystalline powder preparation of anlotinib dihydrochloride. The compound of formula II disclosed herein is a crystalline powder with a flaky crystal habit having a specific surface area ?10 m2/g and a particle-size distribution of X50?50 ?m and/or X90?500 ?m, such that a large specific surface area is provided without reducing the particle size of the drug by a physical method under the condition of a broad particle-size distribution, and the drug can rapidly dissolving. In addition to excellent dissolution property, the crystalline powder is also beneficial to industrial manufacturing, featuring simplified process and cost-efficiency.

Abstract: A solid pharmaceutical composition containing a 1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof and a preparation method therefor. In particular, involved are a solid pharmaceutical composition containing 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazine-2-amine or a pharmaceutically acceptable salt thereof and a preparation method therefor. The solid pharmaceutical composition has a good stability, a fast dissolution rate and a high bioavailability, and is suitable for clinical production and use.

Abstract: Recommending applications based on call requests between applications is disclosed, including: receiving a plurality of sets of application call request recordings from respective ones of a plurality of client devices; using the plurality of sets of application call request recordings to generate association relationships between a first application and one or more other applications; determining a set of application recommendation information determined based at least in part on the association relationships between the first application and the one or more other applications; and sending the set of application recommendation information to a recipient client device.

Abstract: The disclosure provides an experimental calibration method of a redundant inertial measurement unit including, step (1), establishing an installation angle model using a cone descriptive scheme, and obtaining a relationship of an angular speed of a carrier and an angular speed measured by each gyroscope, step (2), establishing a standard calibration model of the redundant inertial measurement unit based on a relationship between a sensor coordinate system and a carrier coordinate system, step (3), establishing a state equation and a measurement equation of a filter, step (4), performing a row amplification of measurement amounts based on the measurement equation established in step (3), and obtaining an amplificated measurement equation for improving observability, and step (5), obtaining a Jacobi matrix and a Hessian matrix based on the amplificated measurement equation, and estimating error parameters by an extended Kalman filtering algorithm based on a second-order Taylor expansion.

Abstract: A pharmaceutical composition comprising dabigatran etexilate, and preparation method and use thereof, and solid preparation comprising the pharmaceutical composition; the pharmaceutical composition comprises a vitamin C layer and a dabigatran etexilate layer separated by a semipermeable film layer, and the semipermeable film layer comprises a water-soluble compound, a water-insoluble compound and an optional anti-sticking agent and/or plasticizer.